Register for our free email digests:
Geron Corp.
www.geron.com
Latest From Geron Corp.
J&J Plans 10 Potential Blockbuster Filings By 2023
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Geron Has Cash, But Does It Have The Imetelstat Data To Push On Without Janssen?
Janssen is dropping the telomerase inhibitor as imetelstat nears the conclusion of Phase II in myelodysplastic syndrome and myelofibrosis, but Geron has $183m in cash on hand that it will use to take the drug forward on its own in one or both indications.
Company Information
- Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Geron Corp.
- Senior Management
-
John A Scarlett, MD, Pres. & CEO
Olivia K Bloom, EVP, Fin. & CFO
Melissa A Behrs, EVP, Bus. Dev.
Andrew J Grethlein, PhD, EVP, Dev. & Technical Operations
Aleksandra Rizo, CMO - Contact Info
-
Geron Corp.
Phone: (650) 473-7700
149 Commonwealth Dr.
Menlo Park, CA 94025
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice